THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING

The side effects of a Genzyme deal

Already benefiting from firm’s production woes, rivals foresee wider opening

The Shire Pharmaceuticals lab in Cambridge. The drug maker hopes to challenge Genzyme with treatments for Gaucher and Fabry diseases. The Shire Pharmaceuticals lab in Cambridge. The drug maker hopes to challenge Genzyme with treatments for Gaucher and Fabry diseases. (David L. Ryan/Globe Staff)
By Robert Weisman
Globe Staff / August 12, 2010

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

Text size +

The potential buyout of Genzyme Corp. , the state’s largest biotechnology company, could be a boon for a pair of foreign-based competitors that have been aggressively marketing rival treatments to challenge Genzyme’s lucrative enzyme replacement drugs. (Full article: 964 words)

This article is available in our archives:

Globe Subscribers

FREE for subscribers

Subscribers to the Boston Globe get unlimited access to our archives.

Not a subscriber?

Non-Subscribers

Purchase an electronic copy of the full article. Learn More

  • $9.95 1 month archives pass
  • $24.95 3 months archives pass
  • $74.95 1 year archives pass